Investor Relations

Overview
Stock
- Stock Quote & Chart
News & Events
Financials
- SEC Filings
Governance
Resources

News Releases

Year

14 Jan '22

LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant

Results from ongoing testing and monitoring of COVID-19 variants shows the rapid microfluidic test detects Omicron at a comparable sensitivity to other variants LONDON , Jan. 14, 2022 /PRNewswire/ -- LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced that

11 Jan '22

LumiraDx has Commenced Shipments in Europe for its COVID-19 & Flu A/B Microfluidic Antigen Test

Company Announces Preliminary Revenue for Fourth Quarter and Full Year 2021 LONDON , Jan. 11, 2022 /PRNewswire/ -- LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced preliminary results for the fourth quarter of 2021 as well as expected full-year revenue.

11 Jan '22

LumiraDx CRP Test Achieves CE Marking

- Rapid microfluidic immunofluorescence assay intended for the quantitative determination of C-reactive protein (CRP) in fingerstick, venous whole blood and plasma specimens within a range of 5.0 - 250.0 mg/L - Quantitative results in 4 minutes from sample application, aids in fast clinical

Investor Tools

Print Page
Email Alerts
RSS Feeds

Request Email Alerts